Personalis, Inc. (FRA:04X)

Market Cap	1.00B +159.5%
Revenue (ttm)	55.95M -24.7%
Net Income	-82.87M
EPS	-0.89
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	9.33
Previous Close	9.50
Day's Range	9.33 - 9.33
52-Week Range	3.66 - 10.10
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Personalis

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 260
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04X

Financial Performance

In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.

Financial numbers in USD